Abstract:The inappropriate activation of complement may contribute to various immune diseases. The alternative pathway (AP) predominates during complement activation regardless of the initiating pathways. Hence, the main AP regulator factor H (FH) holds great potential as an attractive therapeutic intervention. In addition, complement receptor of the immunoglobulin superfamily (CRIg) has been demonstrated to inhibit AP and, more notably, still specifically binds to C3b/iC3b. We thus developed novel CRIg‐targeted complement inhibitors by connecting the functional domains of CRIg and FH, which we termed CRIg‐FH and CRIg‐L‐FH. CRIg‐L‐FH, slightly more potent than CRIg‐FH, considerably inhibited both AP‐ and also classical pathway (CP)‐mediated hemolysis and successfully eliminated the deposition of C3b/iC3b. Kinetic analysis further revealed that the binding affinity constant (KD) of CRIg/FH was in the micromolar range, consistent with its long‐lasting binding to complement‐attacked cells. CRIg‐L‐FH efficiently protected aberrant erythrocytes of patients with paroxysmal nocturnal hemoglobinuria (PNH) from AP‐and CP‐mediated complement damage (IC50 was 22.43 and 64.69 nM, respectively). Moreover, CRIg‐L‐FH was found to inhibit complement activation induced by the anti‐Thy1 antibody in a mesangiopro‐liferative glomerulonephritis (MPGN) rat model. Hence, CRIg‐L‐FH protects glomerular mesangial cells (GMCs) from complement‐mediated injury and proliferative lesions. These findings strongly suggest that CRIg/FH is a potential therapeutic drug candidate for a range of complement‐mediated diseases.—Qiao, Q., Teng, X., Wang, N., Lu, R., Guo, L., Zhang, X., Du, Y., Wang, W., Chen, S., Wu, Q., He, G., Wang, Y., and Hu, W., A novel CRIg‐targeted complement inhibitor protects cells from complement damage. FASEB J. 28, 4986–4999 (2014). www.fasebj.org

Identification Of A Complement Receptor 1 Peptide For Inhibition Of Immune Hemolysis

Selection and characterization of a peptide-based complement modulator targeting C1 of the innate immune system

New Insights into the Complement Receptor of the Ig Superfamily Obtained from Structural and Functional Studies on Two Mutants

Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor

A Novel CRIg‐targeted Complement Inhibitor Protects Cells from Complement Damage

Functional Identification of the Stable Transfection C5ar Cell Line Molt-4

Inactivation of Complement by Recombinant Human C3 Derivatives

Anti-human Properdin Monoclonal Antibody Dose-Dependently Inhibits Complement-Mediated Lysis of PNH Erythrocytes in Ham's Test and Prevents Extravascular Hemolysis in a Human Properdin Transgenic Mouse Model

The Solvent at Antigen-Binding Site Regulated C3d-CR2 Interactions Through the C-terminal Tail of C3d at Different Ion Strengths: Insights from Molecular Dynamics Simulation.

C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia

Co-Expression of the Complement Regulatory Proteins Human Daf and Cd59 with an Ires-Mediated Dicistronic Mammalian Vector Enhances Their Cell Protective Effects

Complement Depletion Improves Human Red Blood Cell Reconstitution in Immunodeficient Mice.

Peptide Inhibitors of C3 Activation As a Novel Strategy of Complement Inhibition for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

A nanobody-based complement inhibitor targeting complement component 2 reduces hemolysis in a complement humanized mouse model of autoimmune hemolytic anemia

CG001, a C3b-targeted complement inhibitor blocks three complement pathways: development and preclinical evaluation

Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy

[Novel therapeutic agents for hemolytic anemia]

An Anti-Endotoxin Peptide That Generates from the Amino-Terminal Domain of Complement Regulatory Protein C1 Inhibitor.

Humanization of a mouse anti-human complement C6 monoclonal antibody as a potential therapeutic for certain complement-mediated diseases

Methods for quantitative detection of antibody-induced complement activation on red blood cells

Mechanistic insights into complement pathway inhibition by CR1 domain duplication